-

Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and directors violated securities laws and breached fiduciary duties to shareholders.

Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and directors violated securities laws and breached fiduciary duties to shareholders.

Share

Why Are We Investigating Sionna Therapeutics?

On Monday, August 10, 2026, Sionna Therapeutics stock plunged 92% to close at $4.51 after the Company reported disappointing results from its Phase 2a proof-of-concept study of SION-719 in cystic fibrosis.

According to media reports, the PreciSION CF trial failed to achieve its key activity endpoint, which measured the reduction in sweat chloride – a key marker of treatment success – when SION-719 was administered alongside the standard-of-care treatment Trikafta.

Though the Company finished the second quarter with "substantial financial resources," it intends to take measures to preserve capital while determining the appropriate path forward for its clinical pipeline.

What Can Shareholders Do Now?

If you lost money investing in Sionna Therapeutics contact Robbins LLP for more information by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP

A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Sionna Therapeutics settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:SION

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Alert: Robbins LLP Informs Investors of the Build-A-Bear Workshop, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Build-A-Bear Workshop faces allegations it misled investors regarding its 2026 financial guidance and overstated its business prospects....

Investor Alert: Robbins LLP Informs Investors of the EyePoint, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--EyePoint allegedly misled investors regarding the efficacy and viability of DURAVYU for the treatment of wet age-related macular degeneration....

Did You Lose Money Investing in CVRx, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against CVRX

SAN DIEGO--(BUSINESS WIRE)--CVRx allegedly misled investors regarding misconduct that exposed the Company to liability under the False Claims Act and Anti-Kickback Statute....
Back to Newsroom